Adhocs
DGAP-Adhoc: MOLOGEN AG resolves to effect a capital increase from authorized capital
19.06.2012 - 11:58 | Quelle: Dow Jones Newswire Web
===
MOLOGEN AG / Key word(s): Capital Increase
19.06.2012 11:57
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Berlin, June 19, 2012
MOLOGEN AG resolves to effect a capital increase from authorized capital
NOT FOR CIRCULATION, PUBLICATION OR FORWARDING IN THE US, CANADA, JAPAN OR
AUSTRALIA.
The management board of MOLOGEN AG (ISIN: DE0006637200) has today resolved
with the consent of the supervisory board to execute a capital increase
with a rights offering to the shareholders. In accordance with Section 4,
paragraph 3 of the bylaws, the capital increase will result from existing
authorized capital of 2011.
The expected proceeds from the capital increase are to strengthen the
equity base. The company intends to use the net proceeds it will receive
primarily for the further development of its product pipeline. In
particular, further clinical trials with the drug candidates MGN1703 and
MGN1601 shall be prepared and implemented.
By issuing up to 3,189,819 new shares, the current share capital of EUR
12,759,275 shall be increased to EUR 15,949,094. The new shares qualify
from the January 1, 2011 onward.
Within the framework of the rights offering, an indirect rights issue will
be extended to the shareholders for the new shares of up to 3,189,819 new
shares. Through publication of the rights offering on June 20, 2012 in the
Federal Gazette ('Bundesanzeiger'), the shareholders of the company will be
invited to exercise their subscription rights in the period from June 21 to
July 5, 2012 (inclusive) to avoid losing them. The subscription ratio is
4:1, i.e. four existing MOLOGEN shares entitle a shareholder to purchase
one new share at the subscription price. As a result of the fractional
shares resulting from the subscription ratio of 4:1, shareholders may not
purchase any new shares for themselves from the individual share portfolio;
they may only purchase one new share or an integral multiple thereof. The
capital increase will be overseen by the quirin bank AG as the sole issuing
bank, which will also act as the subscription agent and is permitted to
subscribe for and acquire the new shares. Trading in subscription rights
will not be organized by either company or the subscription agent and is
not intended by either.
During the subscription period, the subscription price will be determined
on July 2, 2012 at 12:00 CEST, taking into account the current market
situation of the company. The subscription price will be set between (and
including) the weighted average price of the shares in the electronic
trading system XETRA of the Frankfurt Stock Exchange from the beginning of
the subscription period up to the point at which the subscription price is
determined and the current share price of the company at the time of
determining the subscription price. For the determination of the final
subscription price, the company reserves the right to deduct up to 20% from
the first fixed price. The subscription price is at least EUR 1.00 per
share, according to the lowest issue price.
New shares that are made available from rights issued but not exercised
will be offered to interested institutional investors at the subscription
price by the quirin bank AG as part of a public offering in the Federal
Republic of Germany and through an international private placement outside
the United States of America on the basis of Regulation S of the U.S.
Securities Act of 1933 in its currently applicable form, and outside of
Japan, Canada and Australia. The public offering and private placement will
begin on July 6, 2012 and is expected to end on July 9, 2012 at 16:00 CEST.
The approval of the new shares on the regulated market with simultaneous
admission to the sub-segment of the Regulated Market with additional
post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange
is expected to take place on July 13, 2012. The inclusion of the shares in
the current listing is expected to take place on July 16, 2012.
The prospectus, approved by the Federal Agency for Financial Services, has
been published on the website www.mologen.com and is available in hard copy
from the company.
Note:
This ad-hoc announcement is neither an offer for sale of securities nor
solicitation to buy any securities. The information contained in this
announcement is not for circulation in the United States of America (USA)
or within the United States (including its territories and dependencies,
states and the District of Columbia) and may not be forwarded or circulated
to 'U.S. persons' (as defined in Regulation S under the U.S. Securities Act
of 1933 in its currently applicable form ['Securities Act']) or to
publications with a general circulation in the United States. This
announcement is neither an offer nor a solicitation to buy any securities
in the United States. The securities of MOLOGEN AG have not been and will
not be registered under the provisions of the Securities Act and may not be
offered or sold within the United States or to U.S. persons without being
registered or without the presentation of an exemption from the
registration requirements. There will be no public offering of securities
in the United States.
For further informations:
MOLOGEN AG
Fabeckstrasse 30
D-14195 Berlin, Germany
Tel: +49 (0) 30 - 84 17 88 - 0
Investor Relations
Joerg Petraß
investor@mologen.com
Tel: +49 (0) 30 - 84 17 88 - 13
Press Contact
Prof. Peter W. Huebner
huebner@mologen.com
Tel: +49 (0) 30 - 84 17 88 - 38
External Investor Relations
Kirchhoff Consult AG
Jens Hecht
jens.hecht@kirchhoff.de
Tel: +49 (0) 40 - 60 91 86 - 82
19.06.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
===
(END) Dow Jones Newswires
June 19, 2012 05:58 ET (09:58 GMT)
MOLOGEN AG / Key word(s): Capital Increase
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Berlin, June 19, 2012
NOT FOR CIRCULATION, PUBLICATION OR FORWARDING IN THE US, CANADA, JAPAN OR
AUSTRALIA.
The management board of MOLOGEN AG (ISIN: DE0006637200) has today resolved
with the consent of the supervisory board to execute a capital increase
with a rights offering to the shareholders. In accordance with Section 4,
paragraph 3 of the bylaws, the capital increase will result from existing
authorized capital of 2011.
The expected proceeds from the capital increase are to strengthen the
equity base. The company intends to use the net proceeds it will receive
primarily for the further development of its product pipeline. In
particular, further clinical trials with the drug candidates MGN1703 and
MGN1601 shall be prepared and implemented.
By issuing up to 3,189,819 new shares, the current share capital of EUR
12,759,275 shall be increased to EUR 15,949,094. The new shares qualify
from the January 1, 2011 onward.
Within the framework of the rights offering, an indirect rights issue will
be extended to the shareholders for the new shares of up to 3,189,819 new
shares. Through publication of the rights offering on June 20, 2012 in the
Federal Gazette ('Bundesanzeiger'), the shareholders of the company will be
invited to exercise their subscription rights in the period from June 21 to
July 5, 2012 (inclusive) to avoid losing them. The subscription ratio is
4:1, i.e. four existing MOLOGEN shares entitle a shareholder to purchase
one new share at the subscription price. As a result of the fractional
shares resulting from the subscription ratio of 4:1, shareholders may not
purchase any new shares for themselves from the individual share portfolio;
they may only purchase one new share or an integral multiple thereof. The
capital increase will be overseen by the quirin bank AG as the sole issuing
bank, which will also act as the subscription agent and is permitted to
subscribe for and acquire the new shares. Trading in subscription rights
will not be organized by either company or the subscription agent and is
not intended by either.
During the subscription period, the subscription price will be determined
on July 2, 2012 at 12:00 CEST, taking into account the current market
situation of the company. The subscription price will be set between (and
including) the weighted average price of the shares in the electronic
trading system XETRA of the Frankfurt Stock Exchange from the beginning of
the subscription period up to the point at which the subscription price is
determined and the current share price of the company at the time of
determining the subscription price. For the determination of the final
subscription price, the company reserves the right to deduct up to 20% from
the first fixed price. The subscription price is at least EUR 1.00 per
share, according to the lowest issue price.
New shares that are made available from rights issued but not exercised
will be offered to interested institutional investors at the subscription
price by the quirin bank AG as part of a public offering in the Federal
Republic of Germany and through an international private placement outside
the United States of America on the basis of Regulation S of the U.S.
Securities Act of 1933 in its currently applicable form, and outside of
Japan, Canada and Australia. The public offering and private placement will
begin on July 6, 2012 and is expected to end on July 9, 2012 at 16:00 CEST.
The approval of the new shares on the regulated market with simultaneous
admission to the sub-segment of the Regulated Market with additional
post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange
is expected to take place on July 13, 2012. The inclusion of the shares in
the current listing is expected to take place on July 16, 2012.
The prospectus, approved by the Federal Agency for Financial Services, has
been published on the website www.mologen.com and is available in hard copy
from the company.
Note:
This ad-hoc announcement is neither an offer for sale of securities nor
solicitation to buy any securities. The information contained in this
announcement is not for circulation in the United States of America (USA)
or within the United States (including its territories and dependencies,
states and the District of Columbia) and may not be forwarded or circulated
to 'U.S. persons' (as defined in Regulation S under the U.S. Securities Act
of 1933 in its currently applicable form ['Securities Act']) or to
publications with a general circulation in the United States. This
announcement is neither an offer nor a solicitation to buy any securities
in the United States. The securities of MOLOGEN AG have not been and will
not be registered under the provisions of the Securities Act and may not be
offered or sold within the United States or to U.S. persons without being
registered or without the presentation of an exemption from the
registration requirements. There will be no public offering of securities
in the United States.
For further informations:
MOLOGEN AG
Fabeckstrasse 30
D-14195 Berlin, Germany
Tel: +49 (0) 30 - 84 17 88 - 0
Investor Relations
Joerg Petraß
investor@mologen.com
Tel: +49 (0) 30 - 84 17 88 - 13
Press Contact
Prof. Peter W. Huebner
huebner@mologen.com
Tel: +49 (0) 30 - 84 17 88 - 38
External Investor Relations
Kirchhoff Consult AG
Jens Hecht
jens.hecht@kirchhoff.de
Tel: +49 (0) 40 - 60 91 86 - 82
19.06.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
===
(END) Dow Jones Newswires
June 19, 2012 05:58 ET (09:58 GMT)
Im Artikel erwähnt...
-
+0,14% 13,98 L&S MOLOGEN AG
Eröffnung: 0,00 Tageshoch: 13,98 Tagestief: 13,96 Porträt MOLOGEN AG